Cargando…
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis
In patients presenting with acute coronary syndrome (ACS) the optimal duration of dual-antiplatelet therapy after drug-eluting stent (DES) implantation remains unclear. At 6 months after intervention, patients receiving clopidogrel were randomly assigned to either a further 6-month period of placebo...
Autores principales: | Lohaus, Raphaela, Michel, Jonathan, Mayer, Katharina, Lahmann, Anna Lena, Byrne, Robert A., Wolk, Annabelle, ten Berg, Jurrien M., Neumann, Franz-Josef, Han, Yaling, Adriaenssens, Tom, Tölg, Ralph, Seyfarth, Melchior, Maeng, Michael, Zrenner, Bernhard, Jacobshagen, Claudius, Wöhrle, Jochen, Kufner, Sebastian, Morath, Tanja, Ibrahim, Tareq, Bernlochner, Isabell, Fischer, Marcus, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Mehilli, Julinda, Kastrati, Adnan, Schulz-Schüpke, Stefanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021963/ https://www.ncbi.nlm.nih.gov/pubmed/27624287 http://dx.doi.org/10.1038/srep33054 |
Ejemplares similares
-
Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial
por: Gewalt, Senta, et al.
Publicado: (2022) -
High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry
por: Mayer, Katharina, et al.
Publicado: (2023) -
ISAR‐PEBIS (Paclitaxel‐Eluting Balloon Versus Conventional Balloon Angioplasty for In‐Stent Restenosis of Superficial Femoral Artery): A Randomized Trial
por: Ott, Ilka, et al.
Publicado: (2017) -
Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
por: Behnes, Michael, et al.
Publicado: (2022) -
Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus: Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial
por: Koch, Tobias, et al.
Publicado: (2021)